Evidence map›Paper›PMID 35646992›Full record

ArticleFrontiers in medicine2022

The Impact of Active Screening and Management on COVID-19 in Plateau Region of Sichuan, China.

Jia-Jie Lu, Guo-Guo Jiang, Xiang He, Kai-Ju Xu, Hong Yang, Rui Shi, Ying Chen, Yu-Yao Tan, Lang Bai, Hong Tang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Jia-Jie LuCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Guo-Guo JiangDepartment of Hospital Infection Management, Chengdu Second People Hospital, Chengdu, China.
Xiang HeLaboratory of Allergy and Precision Medicine, Chengdu Institute of Respiratory Health, the Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, China.
Kai-Ju XuDepartment of Infectious Diseases, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.
Hong YangPeople's Hospital of Ganzi Tibetan Autonomous Prefecture, Ganzi Tibetan Autonomous Prefecture, Kangding, China.
Rui ShiCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Ying ChenPeople's Hospital of Ganzi Tibetan Autonomous Prefecture, Ganzi Tibetan Autonomous Prefecture, Kangding, China.
Yu-Yao TanPeople's Hospital of Ganzi Tibetan Autonomous Prefecture, Ganzi Tibetan Autonomous Prefecture, Kangding, China.
Lang BaiCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Hong TangCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Guo-Ping LiLaboratory of Allergy and Precision Medicine, Chengdu Institute of Respiratory Health, the Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, China.
Tibet Autonomous Region People's Hospital · CNChengdu Third People's Hospital · CNWest China Hospital of Sichuan University · CNChengdu Second People's Hospital · CNSichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In December 2019, the cases of pneumonia of unknown etiology emerged in Wuhan, China, and rapidly spread throughout the country. The disease was later designated by the World Health Organization (WHO) as Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). Few studies have assessed the clinical characteristics of COVID-19 and control strategies used to mitigate disease spread in high-altitude plateau regions of China. Study Objective: To assess the impact of real-world strategies to control COVID-19 spread in remote plateau regions. Methods: A retrospective study was performed to assess the epidemiology of COVID-19 and strategies used to control disease spread in the high-altitude plateau of Sichuan, China from 24 January 2020 to 19 March 2020. Results: COVID-19 spread and outbreaks in Sichuan were attributed to mass gatherings. A total of 70 patients and 20 asymptomatic individuals were found in the hypoxic plateau region of Sichuan. Twelve patients were admitted after the onset of symptoms, while 58 patients and 20 asymptomatic individuals were found by active screening. The symptomatic patients included those with uncomplicated illness (16/70, 22.9%), mild pneumonia (44/70, 62.9%), and severe pneumonia (10/70, 14.3%). Most patients in the study area showed relatively mild and atypical symptoms such as low or no fever and dyspnea. The incidence of severe pneumonia, fever, dyspnea, and interstitial abnormalities identified by chest CT were all significantly lower in screened patients than those admitted after symptom onset ( Conclusion: Mass gatherings increased risk of spread of SARS-CoV-2 responsible for COVID-19. Active screening and early management have collectively contributed to reduced incidence of severe pneumonia and satisfactory prognoses of infections with COVID-19 in this hypoxic plateau region.

Indexed as

clinical characteristicscontrol strategiesCOVID-19hypoxic plateau areasevere pneumonia

Identifiers

PMID35646992
PMCPMC9131940
OpenAlexW4229456343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.